RGEN Stock Analysis: Repligen | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 8.192m USD | 12M Return: 18.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 126M
EPS Trend: -27.8%
Qual. Beats: 0
Rev. Trend: 55.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality
Repligen Corporation (NASDAQ: RGEN) is a U.S.-based life sciences company headquartered in Waltham, Massachusetts, that develops and commercializes bioprocessing technologies and systems used in the manufacture of biological drugs. Founded in 1981, Repligen sells its products globally across North America, Europe, and Asia Pacific to biopharmaceutical manufacturers, diagnostics companies, contract manufacturing organizations (CMOs), and laboratory researchers.
The companys portfolio spans both upstream and downstream bioprocessing, including hollow fiber consumables, Protein A affinity chromatography resins and pre-packed OPUS columns, filtration systems (such as XCell ATF cell retention devices and KrosFlo tangential flow filtration), and a range of Process Analytical Technology (PAT) tools like PATsmart MAVERICK and the SoloVPE slope spectroscopy system. Repligen also markets products under brands including XCell, TFDF, ProConnex, Spectra/Por, Metenova MixOne, and AVIPure, and maintains a collaboration with Navigo Proteins GmbH to develop affinity ligands.
Repligen operates within the Life Sciences Tools & Services sub-industry, supplying consumables and instruments that support biologic drug development and manufacturing, a segment that has grown alongside the broader rise of monoclonal antibodies and other complex biologic therapies. As a mid-cap company, it sits among specialist vendors that enable biopharma production workflows rather than developing therapeutics directly.
- Protein A resins drive recurring bioprocessing revenue growth
- Cell and gene therapy CDMOs expand filtration product orders
- FDA biologic approvals accelerate bioprocessing capital spending
| Net Income: 51.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.65 > 1.0 |
| NWC/Revenue: 135.6% < 20% (prev 136.4%; Δ -0.76% < -1%) |
| CFO/TA 0.04 > 3% & CFO 130.7m > Net Income 51.4m |
| Net Debt (44.1m) to EBITDA (172.6m): 0.26 < 3 |
| Current Ratio: 9.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.7m) vs 12m ago 0.19% < -2% |
| Gross Margin: 50.25% > 18% (prev 42.72%; Δ 7.53% > 0.5%) |
| Asset Turnover: 26.40% > 50% (prev 22.64%; Δ 3.76% > 0%) |
| Interest Coverage Ratio: 1.75 > 6 (EBIT TTM 78.9m / Interest Expense TTM 45.1m) |
| A: 0.35 (Total Current Assets 1.16b - Total Current Liabilities 126.2m) / Total Assets 2.93b |
| B: 0.16 (Retained Earnings 464.6m / Total Assets 2.93b) |
| C: 0.03 (EBIT TTM 78.9m / Avg Total Assets 2.89b) |
| D: 2.55 (Book Value of Equity 2.11b / Total Liabilities 825.3m) |
| Altman-Z'' = 5.70 = AAA |
| DSRI: 0.87 (Receivables 151.6m/147.4m, Revenue 763.3m/645.7m) |
| GMI: 0.85 (GM 42.72% / 50.25%) |
| AQI: 0.97 (AQ_t 0.51 / AQ_t-1 0.52) |
| SGI: 1.18 (Revenue 763.3m / 645.7m) |
| TATA: -0.03 (NI 51.4m - CFO 130.7m) / TA 2.93b) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of June 30, 2026, the stock is trading at USD 147.01 with a total of 1,875,150 shares traded. Over the past week, the price has changed by +11.35%, over one month by +27.62%, over three months by +28.48% and over the past year by +18.36%.
Current recommended Stop Loss: 134.70 (which is 8.4% or 1.8 ATR below the current price).
Repligen has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy RGEN.
- StrongBuy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 176.1 | 19.8% |
P/E Trailing = 157.8587
P/E Forward = 73.5294
P/S = 10.7319
P/B = 3.8941
P/EG = 2.2927
Revenue TTM = 763.3m USD
EBIT TTM = 78.9m USD
EBITDA TTM = 172.6m USD
Long Term Debt = 546.6m USD (from longTermDebt, last quarter)
Short Term Debt = 21.1m USD (from shortTermDebt, last quarter)
Debt = 828.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 141.0m
Net Debt = 44.1m USD (calculated: Debt 828.7m - CCE 784.5m)
Enterprise Value = 8.24b USD (8.19b + Debt 828.7m - CCE 784.5m)
Interest Coverage Ratio = 1.75 (Ebit TTM 78.9m / Interest Expense TTM 45.1m)
EV/FCF = 79.11x (Enterprise Value 8.24b / FCF TTM 104.1m)
FCF Yield = 1.26% (FCF TTM 104.1m / Enterprise Value 8.24b)
FCF Margin = 13.64% (FCF TTM 104.1m / Revenue TTM 763.3m)
Net Margin = 6.73% (Net Income TTM 51.4m / Revenue TTM 763.3m)
Gross Margin = 50.25% ((Revenue TTM 763.3m - Cost of Revenue TTM 379.8m) / Revenue TTM)
Gross Margin QoQ = 50.70% (prev 47.21%)
Tobins Q-Ratio = 2.81 (Enterprise Value 8.24b / Total Assets 2.93b)
Interest Expense / Debt = 5.45% (Interest Expense 45.1m / Debt 828.7m)
Taxrate = 8.57% (4.82m / 56.2m)
NOPAT = 72.1m (EBIT 78.9m * (1 - 8.57%))
Current Ratio = 9.20 (Total Current Assets 1.16b / Total Current Liabilities 126.2m)
Debt / Equity = 0.39 (Debt 828.7m / totalStockholderEquity, last quarter 2.11b)
Debt / EBITDA = 0.26 (Net Debt 44.1m / EBITDA 172.6m)
Debt / FCF = 0.42 (Net Debt 44.1m / FCF TTM 104.1m)
Total Stockholder Equity = 2.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.78% (Net Income 51.4m / Total Assets 2.93b)
RoE = 2.46% (Net Income TTM 51.4m / Total Stockholder Equity 2.09b)
RoCE = 2.99% (EBIT 78.9m / Capital Employed (Equity 2.09b + L.T.Debt 546.6m))
RoIC = 2.59% (NOPAT 72.1m / Invested Capital 2.79b)
WACC = 8.31% (E(8.19b)/V(9.02b) * Re(8.65%) + D(828.7m)/V(9.02b) * Rd(5.45%) * (1-Tc(0.09)))
Discount Rate = 8.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 33.33 | Cagr: 0.67%
[DCF] Terminal Value 73.45% ; FCFF base≈110.4m ; Y1≈98.6m ; Y5≈82.8m
[DCF] Fair Price = 22.66 (EV 1.32b - Net Debt 44.1m = Equity 1.28b / Shares 56.4m; r=8.35% [WACC [floored]]; 5y FCF grow -13.05% → 2.50% )
EPS Correlation: -27.83 | EPS CAGR: -9.12% | SUE: 0.69 | # QB: 0
Revenue Correlation: 55.63 | Revenue CAGR: 5.03% | SUE: 0.70 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.45 | Chg30d=-0.51% | Revisions=-50% | Analysts=17
EPS next Quarter (2026-09-30): EPS=0.47 | Chg30d=+0.94% | Revisions=-68% | Analysts=17
EPS current Year (2026-12-31): EPS=2.00 | Chg30d=+0.13% | Revisions=+79% | GrowthEPS=+17.1% | GrowthRev=+11.5%
EPS next Year (2027-12-31): EPS=2.55 | Chg30d=-0.19% | Revisions=+33% | GrowthEPS=+27.2% | GrowthRev=+14.8%
[Analyst] Revisions Ratio: +79%